These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24892548)

  • 21. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains.
    Barthelemy PA; Raab H; Appleton BA; Bond CJ; Wu P; Wiesmann C; Sidhu SS
    J Biol Chem; 2008 Feb; 283(6):3639-3654. PubMed ID: 18045863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding.
    de Haard HJ; Kazemier B; van der Bent A; Oudshoorn P; Boender P; van Gemen B; Arends JW; Hoogenboom HR
    Protein Eng; 1998 Dec; 11(12):1267-76. PubMed ID: 9930677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.
    Wörn A; Plückthun A
    Biochemistry; 1998 Sep; 37(38):13120-7. PubMed ID: 9748318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency.
    Rivera-Hernández G; Marin-Argany M; Blasco-Moreno B; Bonet J; Oliva B; Villegas S
    MAbs; 2013; 5(5):678-89. PubMed ID: 23924802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structure of a human VH: requirements for maintaining a monomeric fragment.
    Dottorini T; Vaughan CK; Walsh MA; LoSurdo P; Sollazzo M
    Biochemistry; 2004 Jan; 43(3):622-8. PubMed ID: 14730966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold.
    Jespers L; Schon O; James LC; Veprintsev D; Winter G
    J Mol Biol; 2004 Apr; 337(4):893-903. PubMed ID: 15033359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.
    Tanha J; Nguyen TD; Ng A; Ryan S; Ni F; Mackenzie R
    Protein Eng Des Sel; 2006 Nov; 19(11):503-9. PubMed ID: 16971398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural diversity in a human antibody germline library.
    Teplyakov A; Obmolova G; Malia TJ; Luo J; Muzammil S; Sweet R; Almagro JC; Gilliland GL
    MAbs; 2016; 8(6):1045-63. PubMed ID: 27210805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.
    Douthwaite JA; Sridharan S; Huntington C; Hammersley J; Marwood R; Hakulinen JK; Ek M; Sjögren T; Rider D; Privezentzev C; Seaman JC; Cariuk P; Knights V; Young J; Wilkinson T; Sleeman M; Finch DK; Lowe DC; Vaughan TJ
    MAbs; 2015; 7(1):152-66. PubMed ID: 25484051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bovine IgM antibodies with exceptionally long complementarity-determining region 3 of the heavy chain share unique structural properties conferring restricted VH + Vlambda pairings.
    Saini SS; Farrugia W; Ramsland PA; Kaushik AK
    Int Immunol; 2003 Jul; 15(7):845-53. PubMed ID: 12807823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of the VH repertoire in Canis familiaris.
    Bao Y; Guo Y; Xiao S; Zhao Z
    Vet Immunol Immunopathol; 2010 Sep; 137(1-2):64-75. PubMed ID: 20483487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment.
    Nieba L; Honegger A; Krebber C; Plückthun A
    Protein Eng; 1997 Apr; 10(4):435-44. PubMed ID: 9194169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel selection method for engineered antibodies using the mechanism of Fv fragment stabilization in the presence of antigen.
    Tsumoto K; Nishimiya Y; Kasai N; Ueda H; Nagamune T; Ogasahara K; Yutani K; Tokuhisa K; Matsushima M; Kumagai I
    Protein Eng; 1997 Nov; 10(11):1311-8. PubMed ID: 9514120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.
    Ewert S; Honegger A; Plückthun A
    Biochemistry; 2003 Feb; 42(6):1517-28. PubMed ID: 12578364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points.
    Arbabi-Ghahroudi M; To R; Gaudette N; Hirama T; Ding W; MacKenzie R; Tanha J
    Protein Eng Des Sel; 2009 Feb; 22(2):59-66. PubMed ID: 19033278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity.
    Groves MA; Amanuel L; Campbell JI; Rees DG; Sridharan S; Finch DK; Lowe DC; Vaughan TJ
    MAbs; 2014; 6(1):236-45. PubMed ID: 24256948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme.
    Desmyter A; Transue TR; Ghahroudi MA; Thi MH; Poortmans F; Hamers R; Muyldermans S; Wyns L
    Nat Struct Biol; 1996 Sep; 3(9):803-11. PubMed ID: 8784355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain.
    Riechmann L
    J Mol Biol; 1996 Jun; 259(5):957-69. PubMed ID: 8683598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single domain camel antibodies: current status.
    Muyldermans S
    J Biotechnol; 2001 Jun; 74(4):277-302. PubMed ID: 11526908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.
    Gong R; Wang Y; Ying T; Dimitrov DS
    PLoS One; 2012; 7(8):e42288. PubMed ID: 22879932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.